uniQure (NASDAQ:QURE) Sees Unusually-High Trading Volume After Strong Earnings

uniQure N.V. (NASDAQ:QURE) saw strong trading volume on Monday following a stronger than expected earnings report. 7,361,027 shares were traded during trading, an increase of 197% from the previous session’s volume of 2,476,159 shares.The stock last traded at $9.86 and had previously closed at $15.63.

The biotechnology company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.93) by $0.37. The firm had revenue of $5.57 million for the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure reported Q4 EPS of ($0.56) which beat the consensus loss (~$0.93) and posted revenue of $5.57M (above estimates), showing somewhat better near‑term operating results than expectations. uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
• Neutral Sentiment: Company published full 2025 results and a corporate update and said it held a Type A meeting with the FDA and is evaluating Phase III development considerations; uniQure plans to request a follow‑up Type B meeting in Q2 to clarify next steps. uniQure Announces 2025 Financial Results and Provides Recent Company Updates
• Neutral Sentiment: Market commentary pieces are reassessing uniQure’s valuation and outlook given the new regulatory focus; these analyses may increase trading volume and volatility as investors digest longer approval timelines. Assessing uniQure (QURE) After Sharp Share Price Slide And Gene Therapy Regulatory Focus
• Negative Sentiment: FDA told uniQure its AMT‑130 early‑to‑mid stage data are insufficient to support a marketing application and urged a new randomized trial for the Huntington’s disease gene therapy — a major setback that will likely delay approval, increase development cost and push out potential revenue. FDA tells UniQure study data insufficient for brain disorder therapy application
• Negative Sentiment: News outlets report the FDA decision sent QURE shares plunging (reports of ~40–45% premarket declines), reflecting investor concern about a materially longer path to commercialization for AMT‑130. uniQure Stock Plunges 40% After FDA Shocker
• Negative Sentiment: Multiple securities‑class action lawsuits and law‑firm solicitations allege disclosure failures tied to AMT‑130; ongoing litigation increases legal risk and could be a drag on investor sentiment and resources. uniQure N.V. Sued for Securities Law Violations

Analyst Upgrades and Downgrades

QURE has been the topic of a number of research analyst reports. Wolfe Research initiated coverage on uniQure in a report on Monday, February 23rd. They set a “peer perform” rating on the stock. The Goldman Sachs Group lowered their price objective on shares of uniQure from $56.00 to $38.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 4th. Barclays initiated coverage on shares of uniQure in a report on Tuesday, January 27th. They issued an “equal weight” rating and a $31.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of uniQure in a report on Wednesday, January 14th. Finally, Wall Street Zen cut uniQure from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. Ten research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $58.33.

Insider Buying and Selling at uniQure

In other uniQure news, Director Jack Kaye sold 6,390 shares of the business’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the transaction, the director owned 20,439 shares of the company’s stock, valued at $557,575.92. The trade was a 23.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Matthew C. Kapusta sold 12,378 shares of uniQure stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $23.86, for a total value of $295,339.08. Following the completion of the transaction, the chief executive officer owned 639,076 shares in the company, valued at $15,248,353.36. The trade was a 1.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 50,598 shares of company stock valued at $1,248,588 over the last three months. 4.79% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Jefferies Financial Group Inc. bought a new stake in shares of uniQure in the second quarter valued at approximately $29,217,000. State Street Corp raised its stake in uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after purchasing an additional 1,787,033 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in uniQure by 155.3% in the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after purchasing an additional 1,785,275 shares during the period. Avoro Capital Advisors LLC grew its position in uniQure by 38.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after purchasing an additional 1,705,556 shares during the last quarter. Finally, MPM Bioimpact LLC bought a new position in shares of uniQure during the 4th quarter worth about $33,062,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Price Performance

The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.23. The stock’s 50-day moving average price is $23.46 and its 200 day moving average price is $29.80. The firm has a market cap of $618.00 million, a price-to-earnings ratio of -2.26 and a beta of 0.66.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.